Navigation Links
Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Date:2/24/2011

HAYWARD, Calif., Feb. 24, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, today announced Paul Truex, Anthera's President and Chief Executive Officer, will present at Citi's 2011 Global Health Care Conference in New York, NY on Tuesday, March 1, 2011, at approximately 1:30 pm Eastern Time.Citi 2011 Global Health Care Conference PresentationDate/Time:

Tuesday, March 1, at 1:30 pm Eastern TimeLocation:

Hilton New YorkAbout Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.  Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2.  Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD).  Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Anthera Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results and Operational Update
2. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
4. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
5. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
6. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
7. Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
8. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
9. Savient Pharmaceuticals Announces Executive Appointments
10. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
11. Webcast Alert: Isis Pharmaceuticals 2010 Financial Results and Highlights Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... USA (PRWEB) , ... January 11, 2017 , ... ... the international society for optics and photonics , are commending the U.S. Congress ... following the signing Friday by the President of the American Innovation and Competitiveness ...
(Date:1/11/2017)... CA (PRWEB) , ... January 11, 2017 , ... ... of in-kind scientific grants to ground-breaking microbiome studies. Its most recent microbiome impact ... of Medicine, who will study the effect of long-term use of oral antibiotics, ...
(Date:1/11/2017)... ... ... Back pain relief technology is now available without a prescription at What A ... for WAR members. , This spinal restoration platform boasts utilization of technology that has ... from chronic back pain. , What A Relief Back Pain Centers ( ...
(Date:1/11/2017)... Md. , Jan. 11, 2017  GenVec, ... gene delivery company, announced today that its chief ... present a talk entitled  "AdenoVerseā„¢ platform for translational ... the Biotech Showcase at the upcoming Phacilitate Cell ... Miami , Florida.  Dr. Brough,s presentation ...
Breaking Biology Technology:
(Date:12/15/2016)... ... announced the addition of the "Global Military Biometrics Market 2016-2020" ... military biometrics market to grow at a CAGR of 7.5% during the ... an in-depth market analysis with inputs from industry experts. The report covers ... report also includes a discussion of the key vendors operating in this ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , ... expansion of its patent portfolio, which grew to over 40 granted and ... , , ... recently filed patent entitled " System, Device, and Method Estimating ... that enables device makers to forego costly hardware components needed to estimate ...
Breaking Biology News(10 mins):